{"entity":{"id":"kim-dong-wan","kind":"person","name":"Dong-Wan Kim","aka":[],"tldr":"Dong-Wan Kim is a thoracic oncologist central to the ALK and ROS1 inhibitor trials, from crizotinib to brigatinib and beyond.","summary":"Dong-Wan Kim is Professor of Internal Medicine and a thoracic oncologist at Seoul National University Hospital. He has been an investigator on the PROFILE and ALTA trials and on later ALK and ROS1 inhibitor studies, including lorlatinib and repotrectinib, as well as EGFR studies, helping to establish targeted therapy for fusion-driven lung cancer. His publications include the ALTA-1L trial comparing brigatinib with crizotinib in ALK-positive non-small-cell lung cancer. He remains central to the development of ALK and ROS1 inhibitors, from crizotinib to brigatinib and beyond.","asOf":"2026-09-08","links":[{"label":"Seoul National University Hospital","url":"https://www.snuh.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20DW%5BAuthor%5D%20Seoul%20National%20University%20ALK%20lung"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["alk","ros1"],"drugs":["lorlatinib","repotrectinib"],"companies":[],"institutions":["snuh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Internal Medicine; thoracic oncology","institutionId":"snuh","specialisms":["Lung cancer","ALK and ROS1 fusions","Targeted therapy"],"profiles":[{"label":"Seoul National University Hospital","url":"https://www.snuh.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20DW%5BAuthor%5D%20Seoul%20National%20University%20ALK%20lung"}],"papers":[{"title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer (ALTA-1L)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1810171"},{"title":"CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2027187","doi":"10.1056/NEJMoa2027187"}]},"route":"/people/kim-dong-wan/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/"},{"id":"ros1","kind":"target","name":"ROS1","route":"/targets/ros1/"}],"drug":[{"id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/"},{"id":"repotrectinib","kind":"drug","name":"Repotrectinib","route":"/drugs/repotrectinib/"}],"institution":[{"id":"snuh","kind":"institution","name":"Seoul National University Hospital","route":"/institutions/snuh/"}],"paper":[{"id":"paper-alta-jco-2017","kind":"paper","name":"Brigatinib in patients with crizotinib-refractory ALK-positive non-small-cell lung cancer: a randomized, multicenter phase II trial (ALTA)","route":"/key-papers/paper-alta-jco-2017/"},{"id":"paper-shaw-crown-lorlatinib-crizotinib-nejm-2020","kind":"paper","name":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","route":"/key-papers/paper-shaw-crown-lorlatinib-crizotinib-nejm-2020/"}],"trial":[{"id":"alta","kind":"trial","name":"ALTA","route":"/trials/alta/"}]}}